1. Search Result
Search Result
Results for "

dominant

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

2

Screening Libraries

9

Peptides

4

Natural
Products

1

Recombinant Proteins

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-22167

    Others Others
    Methyl 2-hydroxy-4-methylvalerate is one of dominant volatile compounds in Zhenjiang aromatic vinegar. Methyl 2-hydroxy-4-methylvalerate is used for charting flavour biosynthesis networks of vinegar microbiota .
    Methyl 2-hydroxy-4-methylvalerate
  • HY-145694

    CDK Metabolic Disease
    CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC50s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD) .
    CDK5-IN-3
  • HY-P2203
    SAHM1
    1 Publications Verification

    Notch Inflammation/Immunology
    SAHM1, a peptide mimetic of a dominant negative form of mastermind-like (MAML), inhibits canonical Notch transcription complex formation. SAHM1 can be used for the research of allergic airway inflammation in mice .
    SAHM1
  • HY-139290

    RG4326

    MicroRNA Metabolic Disease Cancer
    RGLS4326 (RG4326) is a first-in-class, short oligonucleotide inhibitor of microRNA-17 (miR-17). RGLS4326 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 inhibits miR-17 function in HeLa cells with an EC50 value of 28.3 nM .
    RGLS4326
  • HY-146272

    Vasopressin Receptor Metabolic Disease
    Vasopressin V2 receptor antagonist 1 (Compound 4g) is a vasopressin V2 receptor (V2R) antagonist with a Ki of 3.8 nM. Vasopressin V2 receptor antagonist 1 can be used for autosomal dominant polycystic kidney disease (ADPKD) research .
    Vasopressin V2 receptor antagonist 1
  • HY-151878

    CDK GSK-3 Metabolic Disease
    CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC50 value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .
    CDK7-IN-20
  • HY-149770

    Cytochrome P450 Metabolic Disease
    CYP4A11/CYP4F2-IN-2 (compound 15) is an orally available inhibitor of CYP4A11/4F2 with IC50s of 120 nM and 220 nM, respectively. CYP4A11/CYP4F2-IN-2 inhibits 20-HETE production in rat kidney and has potential inhibitory effects on diabetic nephropathy and autosomal dominant polycystic kidney disease .
    CYP4A11/CYP4F2-IN-2
  • HY-N10348

    Others Endocrinology
    Progoitrin is the dominant glucosinolate in incriminated crops. Antithyroid activity .
    Progoitrin
  • HY-N8731

    Helenien

    Others Metabolic Disease
    Lutein dipalmitate (Helenien), a Lutein ester, is a dominant compound in Lutein supplement .
    Lutein dipalmitate
  • HY-153911

    Others Endocrinology
    H2-Gamendazole is a derivative of Lonidamine that reduces cyst formation in polycystic kidney disease and is used in autosomal dominant polycystic kidney disease research .
    H2-Gamendazole
  • HY-113157

    Drug Metabolite Endogenous Metabolite Others
    Estrone 3-glucuronide is deuterium labeled Estrone 3-glucuronide. Estrone 3-glucuronide, the dominant metabolite of estradiol, is determined to be the urinary marker for prediction of the fertile window .
    Estrone 3-glucuronide
  • HY-U00036A

    LY519818

    PPAR Metabolic Disease
    Naveglitazar (LY519818) is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models .
    Naveglitazar
  • HY-106844A

    Others Cardiovascular Disease
    (+)-EMD 57033 is a cardiac troponin C (cTnC) activator, is a dominant Ca 2+ sensitizer. (+)-EMD 57033 binds the cardiac/slow skeletal troponin C isoform and exerts myocardial contractile promotion function .
    (+)-EMD 57033
  • HY-U00036

    LY519818 racemate

    PPAR Metabolic Disease
    Naveglitazar racemate (LY519818 racemate) is the racemate of Naveglitazar. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models .
    Naveglitazar racemate
  • HY-P3838

    PKC Others
    Protein Kinase C γ Peptide is a peptide fragment of Protein Kinase Cγ. Protein Kinase Cγ is a protein causative for dominant ataxia, that can negatively regulate nuclear import of recessive-ataxia-related aprataxin .
    Protein Kinase C γ Peptide
  • HY-150245

    Huntingtin Neurological Disease
    mHTT-IN-1 (Example 1) is a potent mutant huntingtin (mHTT) inhibitor. mHTT is toxic and a major cause of the inherited autosomal dominant neurodegenerative disorder, Huntington's disease (HD). mHTT-IN-1 conducts the reduction of mHTT with an EC50 value of 46 nM .
    mHTT-IN-1
  • HY-16743
    Ibiglustat
    2 Publications Verification

    Venglustat; SAR402671; GZ402671

    Glucosylceramide Synthase (GCS) Metabolic Disease
    Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat
  • HY-121432

    Others Others
    Kitol is peptide used for after-sun repair cosmetics. The dominant degradation reaction for vitamin A derivatives is heat-induced formation of kitols, i.e., dimers or higher oligomers. Vitamin A esters are used as a model system to evaluate microcalorimetry as a tool for monitoring the stability of heat-sensitive substances .
    Kitol
  • HY-16743B
    Ibiglustat succinate
    2 Publications Verification

    Venglustat succinate; SAR402671 succinate; GZ402671 succinate

    Glucosylceramide Synthase (GCS) Neurological Disease
    Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat succinate
  • HY-16743A
    Ibiglustat (L-Malic acid)
    2 Publications Verification

    Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid)

    Glucosylceramide Synthase (GCS) Metabolic Disease
    Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat (L-Malic acid)
  • HY-145693

    CDK Others
    CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor with IC50s of 0.2 and 23 for CDK5/p25 and CDK2/CycA, respectively .
    CDK5-IN-2
  • HY-129065
    Nourseothricin sulfate
    1 Publications Verification

    Streptothricin sulfate

    Fungal Bacterial Antibiotic Infection
    Nourseothricin sulfate (Streptothricin sulfate) is a broad-spectrum antibiotic that destroys the outer membrane of Gram-negative bacteria and is a dominant selective marker for Fonsecaea pedrosoi . Nourseothricin sulfate inhibits protein biosynthesis in prokaryotic cells and strongly inhibits the growth of eukaryotes like fungi and can also be used as a elective marker for a wide range of organisms including bacteria, yeast, filamentous fungi, and plant cells .
    Nourseothricin sulfate
  • HY-144117

    CDK Metabolic Disease
    GFB-12811 is a high selective and orally active CDK5 inhibitor with an IC50 of 2.3 nM. GFB-12811 is highly selective over the other tested kinases (CDK1/2/6/7/9) .
    GFB-12811
  • HY-P5503

    HIV Others
    Pol (476-484), HIV-1 RT Epitope is a biological active peptide. (This is a reverse transcriptase (RT) epitope (Pol residues 476-484). Within HIV-1 RT the peptide appears to be the dominant HLA A*0201-restricted epitope. Was used to investigate possible mechanisms behind HIV-1 escape from CTL. IV9 is the actual epitope processed and presented in HIV-1-infected cell lines.)
    Pol (476-484), HIV-1 RT Epitope

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: